Leaflet RALTEGRAVIR VIATRIS 600mg film-coated tablets
Indicated for: HIV-1 infection
Route of administration: oral
Substance: raltegravir (integrase inhibitor)
ATC: J05AJ01 (Antiinfectives for systemic use | Direct acting antivirals | Integrase inhibitors)
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
Raltegravir is a medication used for the treatment of human immunodeficiency virus (HIV) infection. It is an integrase inhibitor that prevents the integration of viral DNA into the host cell genome, thereby reducing viral replication.
The medication is taken orally, usually in tablet form, and should be used in combination with other antiretroviral drugs as directed by your doctor. It is important to adhere to the treatment regimen to prevent the development of viral resistance.
Side effects may include nausea, fatigue, headache, or insomnia. In rare cases, severe adverse effects such as allergic reactions or liver function impairment may occur, requiring immediate medical attention.
Patients should inform their doctor about any other medications being used or pre-existing conditions, such as liver diseases, to ensure the safe use of raltegravir.
General data about RALTEGRAVIR VIATRIS 600mg
- Substance: raltegravir
- Date of latest medicines list: 01-10-2025
- Product code: W71328001
- Concentration: 600mg
- Pharmaceutical form: film-coated tablets
- Quantity: 60
- Product type: Generic medicine
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for raltegravir
Concentrations available for raltegravir
- 100mg
- 400mg
- 600mg